ARECOR GRANTED KEY U.S. PATENT PROTECTING PROPRIETARY INSULIN PRODUCTS
March 23, 2022 08:00 ET
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Group”) ARECOR GRANTED KEY U.S. PATENT PROTECTING PROPRIETARY INSULIN PRODUCTS Further strengthens the Company’s extensive patent portfolio protecting its...
BUSINESS UPDATE
January 20, 2022 07:01 ET
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor”, the “Company” or the “Group”) BUSINESS UPDATEMomentum continues across partnered and proprietary portfolio Cambridge, UK, 20 January 2022: Arecor Therapeutics plc...
ARECOR COMMENCES US PHASE I CLINICAL TRIAL OF AT247 ULTRA-RAPID INSULIN IN COMBINATION WITH AN INSULIN PUMP
January 20, 2022 07:00 ET
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Group”) ARECOR COMMENCES US PHASE I CLINICAL TRIAL OF AT247 ULTRA-RAPID INSULIN IN COMBINATION WITH AN INSULIN PUMP First patient dosed in potential...
ARECOR ANNOUNCES AN EXCLUSIVE FORMULATION STUDY COLLABORATION WITH A LEADING GLOBAL MEDICAL PRODUCTS COMPANY TO DEVELOP A STABLE READY TO ADMINISTER PRODUCT
November 01, 2021 07:00 ET
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Group”) ARECOR ANNOUNCES AN EXCLUSIVE FORMULATION STUDY COLLABORATION WITHA LEADING GLOBAL MEDICAL PRODUCTS COMPANY TO DEVELOP A STABLE READY TO ADMINISTER...
Arecor Announces Positive Headline Results From First Phase i Clinical Trial of At278 Ultra-Concentrated Ultra-Rapid Acting Insulin Candidate for Diabetes
September 20, 2021 08:39 ET
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor”, the “Company” or the “Group”) ARECOR ANNOUNCES POSITIVE HEADLINE RESULTS FROM FIRST PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN...
Arecor Announces an Exclusive Formulation Study Collaboration With Lilly
May 20, 2021 03:48 ET
|
Arecor Therapeutics PLC
CAMBRIDGE, United Kingdom, May 20, 2021 (GLOBE NEWSWIRE) -- Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today...
Arecor Receives £2.8 Million Grant Award From Innovate UK
March 31, 2021 04:00 ET
|
Arecor Ltd
CAMBRIDGE, United Kingdom, March 31, 2021 (GLOBE NEWSWIRE) -- Arecor Limited ("Arecor" or "the Company"), the biopharmaceutical company advancing today's therapies to enable healthier lives, today...
Arecor's Partner Inhibrx Exercises Its Option to License a New Formulation Developed by Arecor in Accordance With the Terms of Formulation Development Agreement
December 17, 2020 03:00 ET
|
Arecor Ltd
CAMBRIDGE, United Kingdom, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Arecor Ltd ("Arecor" or "the Company"), the biopharmaceutical company advancing today's therapies to enable healthier lives, today...
Arecor Announces Publication of Phase I Data for AT247 in Diabetes Care
December 16, 2020 04:31 ET
|
Arecor Ltd
CAMBRIDGE, United Kingdom, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Arecor Limited ("Arecor" or "the Company"), the biopharmaceutical company advancing today's therapies to enable healthier lives, today...
Arecor Limited: First Patient Dosed in Phase I Clinical Trial of Ultra-Concentrated Rapid Acting Insulin Candidate, AT278, for Diabetes
December 15, 2020 12:38 ET
|
Arecor Ltd
CAMBRIDGE, United Kingdom, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Arecor Limited ("Arecor" or "the Company"), the biopharmaceutical company advancing today's therapies to enable healthier lives announces...